Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2025 | Urine-based tool predicts immunotherapy response in bladder cancer

Félix Guerrero-Ramos, MD, PhD, Hospital Universitario 12 de Octubre, Madrid, Spain, describes the development of BlaDimiRplus, a novel urine-based method to predict response to bacillus Calmette-Guérin (BCG) immunotherapy in non-muscle-invasive bladder cancer (NMBIC). This strategy integrates miRNA and cytokine profiling to identify likely responders before treatment. Data from a BCG-treated cohort showed strong predictive performance for select biomarkers, with improved accuracy when combined. This interview took place at the 2025 European Association of Urology (EAU) Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.